首页> 外文期刊>Human Molecular Genetics >LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity
【24h】

LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity

机译:LRRK2通过降低Rab7活性来阻止晚期内体出芽,从而延迟了降解性受体的运输。

获取原文
获取原文并翻译 | 示例
           

摘要

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset autosomal dominant Parkinson's disease (PD), and sequence variations at the LRRK2 locus are associated with increased risk for sporadic PD. LRRK2 contains both GTPase and kinase domains flanked by protein interaction motifs, and mutations associated with familial PD have been described for both catalytic domains. LRRK2 has been implicated in diverse cellular processes, and recent evidence pinpoints to an important role for LRRK2 in modulating a variety of intracellular membrane trafficking pathways. However, the underlying mechanisms are poorly understood. Here, by studying the classical, well-understood, degradative trafficking pathway of the epidermal growth factor receptor (EGFR), we show that LRRK2 regulates endocytic membrane trafficking in an Rab7-dependent manner. Mutant LRRK2 expression causes a slight delay in early-to-late endosomal trafficking, and a pronounced delay in trafficking out of late endosomes, which become aberrantly elongated into tubules. This is accompanied by a delay in EGFR degradation. The LRRK2-mediated deficits in EGFR trafficking and degradation can be reverted upon coexpression of active Rab7 and of a series of proteins involved in bridging the EGFR to Rab7 on late endosomes. Effector pulldown assays indicate that pathogenic LRRK2 decreases Rab7 activity both in cells overexpressing LRRK2, as well as in fibroblasts from pathogenic mutant LRRK2 PD patients when compared with healthy controls. Together, these findings provide novel insights into a previously unknown regulation of Rab7 activity by mutant LRRK2 which impairs membrane trafficking at very late stages of the endocytic pathway.
机译:富含亮氨酸的重复激酶2(LRRK2)基因中的突变会导致迟发性常染色体显性帕金森氏病(PD),并且LRRK2基因座处的序列变异与散发PD的风险增加相关。 LRRK2包含侧接蛋白相互作用基序的GTPase和激酶结构域,并且对于两个催化结构域均已描述了与家族性PD相关的突变。 LRRK2与多种细胞过程有关,最近的证据指出了LRRK2在调节多种细胞内膜运输途径中的重要作用。但是,基本机制了解得很少。在这里,通过研究表皮生长因子受体(EGFR)的经典的,易于理解的,降解的运输途径,我们表明LRRK2以Rab7依赖性方式调节内吞膜运输。突变的LRRK2表达导致早期至晚期的内体运输略有延迟,并显着延迟了晚期内体的运输,内体则异常延长成小管。这伴随着EGFR降解的延迟。 EGFR转运和降解的LRRK2介导的缺陷可在活性Rab7和晚期内体上将EGFR桥接至Rab7的一系列蛋白质的共表达中得到恢复。效应物下拉试验表明,与健康对照相比,致病性LRRK2会在过量表达LRRK2的细胞以及致病性突变LRRK2 PD患者的成纤维细胞中降低Rab7活性。总之,这些发现为突变LRRK2对Rab7活性的先前未知调节提供了新的见解,该突变削弱了在内吞途径后期的膜运输。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号